Previous 10 | Next 10 |
2023-10-26 17:46:55 ET More on Monte Rosa Therapeutics Roche in pact with Monte Rosa to develop cancer and neuro drugs Seeking Alpha’s Quant Rating on Monte Rosa Therapeutics Historical earnings data for Monte Rosa Therapeutics Financial information fo...
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has raised $25 million at-the-market from a life sciences-dedicated invest...
2023-10-19 10:00:13 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further...
2023-10-17 09:31:32 ET DENVER, Colo., Oct 17, 2023 ( www.247marketnews.com )- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) disclosed, this morning, that it entered into a strategic collaboration and licensing agreement with Roche, one of the largest global healthcare companies, to disco...
2023-10-17 08:20:15 ET More on Monte Rosa Seeking Alpha’s Quant Rating on Monte Rosa Therapeutics Historical earnings data for Monte Rosa Therapeutics Financial information for Monte Rosa Therapeutics For further details see: Roche in pact with Mon...
Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies Tumor size reductions observed in patients with biomarker-positive tumors Safety profile supports further clinical development of MR...
Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEEN TM discovery engine with Roche’s strong expertise in delivering transformative therapies to patients Monte Rosa to receive an upfront payment of $50 million and potential future payment...
2023-08-10 10:19:33 ET Monte Rosa Therapeutics press release ( NASDAQ: GLUE ): Q2 GAAP EPS of -$0.71. Cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2023, were $207.6 million, compared to cash, cash equivalents, restricted cash, and marke...
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023 Received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for MRT-2359 for the treatment of small cell lung cancer (SCLC) Announced dev...
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning i...
News, Short Squeeze, Breakout and More Instantly...
Monte Rosa Therapeutics Inc. Company Name:
GLUE Stock Symbol:
NASDAQ Market:
Monte Rosa Therapeutics Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside cha...
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 202...
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected ...